The Experts below are selected from a list of 57105 Experts worldwide ranked by ideXlab platform
Gustavo Saposnik - One of the best experts on this subject based on the ideXlab platform.
-
high efficacy disease modifying therapies in people with relapsing remitting multiple sclerosis the role of Risk Attitude in treatment decisions
The Patient: Patient-Centered Outcomes Research, 2021Co-Authors: Jorge Maurino, Javier Sotoca, Ángel P. Sempere, Luis Brieva, Ana B. Caminero, María Terzaghi, Carlos Lopez De Silanes, Julia Graciagil, Gustavo SaposnikAbstract:BACKGROUND Risk Attitude is defined as the willingness to tolerate Risk to achieve a greater expected return. Limited information is available on how relapsing-remitting multiple sclerosis people's perceptions about disease trajectory and Risk Attitude may influence treatment choices. METHODS A non-interventional study applying principles of behavioral economics was conducted to assess willingness to receive unwarranted high-efficacy disease-modifying therapy (DMT) according to best-practice guidelines. People with relapsing-remitting multiple sclerosis (PwRRMS) according to 2010 McDonald criteria completed a survey on symptom severity, Risk preferences, and management of simulated case scenarios mimicking the current treatment landscape. PwRRMS's choice for high-efficacy agents was established as the participant's selection of monoclonal antibodies for case scenarios with at least 2 years of clinical and radiological stability. RESULTS A total of 211 PwRRMS were studied (mean age 39.1 ± 9.5 years, 70.1% female, mean Expanded Disability Status Scale score 1.8 ± 1.1). Almost 50% (n = 96) opted for a high-efficacy DMT despite the lack of evidence of disease activity. Younger age and Risk-seeking behavior were associated with an increased likelihood of selecting unwarranted high-efficacy DMT [odds ratio (OR) 2.00, 95% confidence interval (CI) 1.02-3.93, p = 0.043, and OR 2.17, 95% CI 1.09-4.30, p = 0.027, respectively]. Clinical characteristics or subjective perception of symptom severity had no influence on participants' treatment choices. CONCLUSION Identifying PwRRMS with Risk-seeking behavior would be crucial to implementing specific educational strategies to manage information on disease prognosis, treatment expectations, and safety Risk knowledge.
-
High-Efficacy Disease-Modifying Therapies in People with Relapsing–Remitting Multiple Sclerosis: The Role of Risk Attitude in Treatment Decisions
The Patient - Patient-Centered Outcomes Research, 2020Co-Authors: Jorge Maurino, Javier Sotoca, Ángel P. Sempere, Luis Brieva, Carlos López De Silanes, Ana B. Caminero, María Terzaghi, Julia Gracia-gil, Gustavo SaposnikAbstract:Background Risk Attitude is defined as the willingness to tolerate Risk to achieve a greater expected return. Limited information is available on how relapsing–remitting multiple sclerosis people’s perceptions about disease trajectory and Risk Attitude may influence treatment choices. Methods A non-interventional study applying principles of behavioral economics was conducted to assess willingness to receive unwarranted high-efficacy disease-modifying therapy (DMT) according to best-practice guidelines. People with relapsing–remitting multiple sclerosis (PwRRMS) according to 2010 McDonald criteria completed a survey on symptom severity, Risk preferences, and management of simulated case scenarios mimicking the current treatment landscape. PwRRMS’s choice for high-efficacy agents was established as the participant’s selection of monoclonal antibodies for case scenarios with at least 2 years of clinical and radiological stability. Results A total of 211 PwRRMS were studied (mean age 39.1 ± 9.5 years, 70.1% female, mean Expanded Disability Status Scale score 1.8 ± 1.1). Almost 50% ( n = 96) opted for a high-efficacy DMT despite the lack of evidence of disease activity. Younger age and Risk-seeking behavior were associated with an increased likelihood of selecting unwarranted high-efficacy DMT [odds ratio (OR) 2.00, 95% confidence interval (CI) 1.02–3.93, p = 0.043, and OR 2.17, 95% CI 1.09–4.30, p = 0.027, respectively]. Clinical characteristics or subjective perception of symptom severity had no influence on participants’ treatment choices. Conclusion Identifying PwRRMS with Risk-seeking behavior would be crucial to implementing specific educational strategies to manage information on disease prognosis, treatment expectations, and safety Risk knowledge.
Jorge Maurino - One of the best experts on this subject based on the ideXlab platform.
-
high efficacy disease modifying therapies in people with relapsing remitting multiple sclerosis the role of Risk Attitude in treatment decisions
The Patient: Patient-Centered Outcomes Research, 2021Co-Authors: Jorge Maurino, Javier Sotoca, Ángel P. Sempere, Luis Brieva, Ana B. Caminero, María Terzaghi, Carlos Lopez De Silanes, Julia Graciagil, Gustavo SaposnikAbstract:BACKGROUND Risk Attitude is defined as the willingness to tolerate Risk to achieve a greater expected return. Limited information is available on how relapsing-remitting multiple sclerosis people's perceptions about disease trajectory and Risk Attitude may influence treatment choices. METHODS A non-interventional study applying principles of behavioral economics was conducted to assess willingness to receive unwarranted high-efficacy disease-modifying therapy (DMT) according to best-practice guidelines. People with relapsing-remitting multiple sclerosis (PwRRMS) according to 2010 McDonald criteria completed a survey on symptom severity, Risk preferences, and management of simulated case scenarios mimicking the current treatment landscape. PwRRMS's choice for high-efficacy agents was established as the participant's selection of monoclonal antibodies for case scenarios with at least 2 years of clinical and radiological stability. RESULTS A total of 211 PwRRMS were studied (mean age 39.1 ± 9.5 years, 70.1% female, mean Expanded Disability Status Scale score 1.8 ± 1.1). Almost 50% (n = 96) opted for a high-efficacy DMT despite the lack of evidence of disease activity. Younger age and Risk-seeking behavior were associated with an increased likelihood of selecting unwarranted high-efficacy DMT [odds ratio (OR) 2.00, 95% confidence interval (CI) 1.02-3.93, p = 0.043, and OR 2.17, 95% CI 1.09-4.30, p = 0.027, respectively]. Clinical characteristics or subjective perception of symptom severity had no influence on participants' treatment choices. CONCLUSION Identifying PwRRMS with Risk-seeking behavior would be crucial to implementing specific educational strategies to manage information on disease prognosis, treatment expectations, and safety Risk knowledge.
-
High-Efficacy Disease-Modifying Therapies in People with Relapsing–Remitting Multiple Sclerosis: The Role of Risk Attitude in Treatment Decisions
The Patient - Patient-Centered Outcomes Research, 2020Co-Authors: Jorge Maurino, Javier Sotoca, Ángel P. Sempere, Luis Brieva, Carlos López De Silanes, Ana B. Caminero, María Terzaghi, Julia Gracia-gil, Gustavo SaposnikAbstract:Background Risk Attitude is defined as the willingness to tolerate Risk to achieve a greater expected return. Limited information is available on how relapsing–remitting multiple sclerosis people’s perceptions about disease trajectory and Risk Attitude may influence treatment choices. Methods A non-interventional study applying principles of behavioral economics was conducted to assess willingness to receive unwarranted high-efficacy disease-modifying therapy (DMT) according to best-practice guidelines. People with relapsing–remitting multiple sclerosis (PwRRMS) according to 2010 McDonald criteria completed a survey on symptom severity, Risk preferences, and management of simulated case scenarios mimicking the current treatment landscape. PwRRMS’s choice for high-efficacy agents was established as the participant’s selection of monoclonal antibodies for case scenarios with at least 2 years of clinical and radiological stability. Results A total of 211 PwRRMS were studied (mean age 39.1 ± 9.5 years, 70.1% female, mean Expanded Disability Status Scale score 1.8 ± 1.1). Almost 50% ( n = 96) opted for a high-efficacy DMT despite the lack of evidence of disease activity. Younger age and Risk-seeking behavior were associated with an increased likelihood of selecting unwarranted high-efficacy DMT [odds ratio (OR) 2.00, 95% confidence interval (CI) 1.02–3.93, p = 0.043, and OR 2.17, 95% CI 1.09–4.30, p = 0.027, respectively]. Clinical characteristics or subjective perception of symptom severity had no influence on participants’ treatment choices. Conclusion Identifying PwRRMS with Risk-seeking behavior would be crucial to implementing specific educational strategies to manage information on disease prognosis, treatment expectations, and safety Risk knowledge.
Milton C Weinstein - One of the best experts on this subject based on the ideXlab platform.
-
the relationship between Risk Attitude and treatment choice in patients with relapsing remitting multiple sclerosis
Medical Decision Making, 2002Co-Authors: Lisa A Prosser, Karen M Kuntz, Amit Baror, Milton C WeinsteinAbstract:Background. Many patients with multiple sclerosis (MS) eligible for β-interferons or glatiramer acetate have chosen to forgo or discontinue treatment. The objective of this study was to evaluate Risk Attitude as a patient characteristic related to treatment choice for patients with MS.Methods. Sixty-two MS patients completed a survey on treatment history, Risk preference, and socioeconomic and clinical variables. Multinomial logistic regression was used to assess the relationship between treatment choice and Risk Attitude. Risk Attitude was measured using a standard gamble question on short-term health outcomes.Results. More Risk-seeking patients were less likely to choose treatment compared with more Risk-averse patients (P < 0.01). For patients who discontinued treatment, the explanatory variable of significance was severity of side effects (P < 0.05).Conclusions. Risk Attitude is a patient characteristic related to treatment initiation in patients with MS. This could be an important factor to consider ...
Javier Sotoca - One of the best experts on this subject based on the ideXlab platform.
-
high efficacy disease modifying therapies in people with relapsing remitting multiple sclerosis the role of Risk Attitude in treatment decisions
The Patient: Patient-Centered Outcomes Research, 2021Co-Authors: Jorge Maurino, Javier Sotoca, Ángel P. Sempere, Luis Brieva, Ana B. Caminero, María Terzaghi, Carlos Lopez De Silanes, Julia Graciagil, Gustavo SaposnikAbstract:BACKGROUND Risk Attitude is defined as the willingness to tolerate Risk to achieve a greater expected return. Limited information is available on how relapsing-remitting multiple sclerosis people's perceptions about disease trajectory and Risk Attitude may influence treatment choices. METHODS A non-interventional study applying principles of behavioral economics was conducted to assess willingness to receive unwarranted high-efficacy disease-modifying therapy (DMT) according to best-practice guidelines. People with relapsing-remitting multiple sclerosis (PwRRMS) according to 2010 McDonald criteria completed a survey on symptom severity, Risk preferences, and management of simulated case scenarios mimicking the current treatment landscape. PwRRMS's choice for high-efficacy agents was established as the participant's selection of monoclonal antibodies for case scenarios with at least 2 years of clinical and radiological stability. RESULTS A total of 211 PwRRMS were studied (mean age 39.1 ± 9.5 years, 70.1% female, mean Expanded Disability Status Scale score 1.8 ± 1.1). Almost 50% (n = 96) opted for a high-efficacy DMT despite the lack of evidence of disease activity. Younger age and Risk-seeking behavior were associated with an increased likelihood of selecting unwarranted high-efficacy DMT [odds ratio (OR) 2.00, 95% confidence interval (CI) 1.02-3.93, p = 0.043, and OR 2.17, 95% CI 1.09-4.30, p = 0.027, respectively]. Clinical characteristics or subjective perception of symptom severity had no influence on participants' treatment choices. CONCLUSION Identifying PwRRMS with Risk-seeking behavior would be crucial to implementing specific educational strategies to manage information on disease prognosis, treatment expectations, and safety Risk knowledge.
-
High-Efficacy Disease-Modifying Therapies in People with Relapsing–Remitting Multiple Sclerosis: The Role of Risk Attitude in Treatment Decisions
The Patient - Patient-Centered Outcomes Research, 2020Co-Authors: Jorge Maurino, Javier Sotoca, Ángel P. Sempere, Luis Brieva, Carlos López De Silanes, Ana B. Caminero, María Terzaghi, Julia Gracia-gil, Gustavo SaposnikAbstract:Background Risk Attitude is defined as the willingness to tolerate Risk to achieve a greater expected return. Limited information is available on how relapsing–remitting multiple sclerosis people’s perceptions about disease trajectory and Risk Attitude may influence treatment choices. Methods A non-interventional study applying principles of behavioral economics was conducted to assess willingness to receive unwarranted high-efficacy disease-modifying therapy (DMT) according to best-practice guidelines. People with relapsing–remitting multiple sclerosis (PwRRMS) according to 2010 McDonald criteria completed a survey on symptom severity, Risk preferences, and management of simulated case scenarios mimicking the current treatment landscape. PwRRMS’s choice for high-efficacy agents was established as the participant’s selection of monoclonal antibodies for case scenarios with at least 2 years of clinical and radiological stability. Results A total of 211 PwRRMS were studied (mean age 39.1 ± 9.5 years, 70.1% female, mean Expanded Disability Status Scale score 1.8 ± 1.1). Almost 50% ( n = 96) opted for a high-efficacy DMT despite the lack of evidence of disease activity. Younger age and Risk-seeking behavior were associated with an increased likelihood of selecting unwarranted high-efficacy DMT [odds ratio (OR) 2.00, 95% confidence interval (CI) 1.02–3.93, p = 0.043, and OR 2.17, 95% CI 1.09–4.30, p = 0.027, respectively]. Clinical characteristics or subjective perception of symptom severity had no influence on participants’ treatment choices. Conclusion Identifying PwRRMS with Risk-seeking behavior would be crucial to implementing specific educational strategies to manage information on disease prognosis, treatment expectations, and safety Risk knowledge.
Ana B. Caminero - One of the best experts on this subject based on the ideXlab platform.
-
high efficacy disease modifying therapies in people with relapsing remitting multiple sclerosis the role of Risk Attitude in treatment decisions
The Patient: Patient-Centered Outcomes Research, 2021Co-Authors: Jorge Maurino, Javier Sotoca, Ángel P. Sempere, Luis Brieva, Ana B. Caminero, María Terzaghi, Carlos Lopez De Silanes, Julia Graciagil, Gustavo SaposnikAbstract:BACKGROUND Risk Attitude is defined as the willingness to tolerate Risk to achieve a greater expected return. Limited information is available on how relapsing-remitting multiple sclerosis people's perceptions about disease trajectory and Risk Attitude may influence treatment choices. METHODS A non-interventional study applying principles of behavioral economics was conducted to assess willingness to receive unwarranted high-efficacy disease-modifying therapy (DMT) according to best-practice guidelines. People with relapsing-remitting multiple sclerosis (PwRRMS) according to 2010 McDonald criteria completed a survey on symptom severity, Risk preferences, and management of simulated case scenarios mimicking the current treatment landscape. PwRRMS's choice for high-efficacy agents was established as the participant's selection of monoclonal antibodies for case scenarios with at least 2 years of clinical and radiological stability. RESULTS A total of 211 PwRRMS were studied (mean age 39.1 ± 9.5 years, 70.1% female, mean Expanded Disability Status Scale score 1.8 ± 1.1). Almost 50% (n = 96) opted for a high-efficacy DMT despite the lack of evidence of disease activity. Younger age and Risk-seeking behavior were associated with an increased likelihood of selecting unwarranted high-efficacy DMT [odds ratio (OR) 2.00, 95% confidence interval (CI) 1.02-3.93, p = 0.043, and OR 2.17, 95% CI 1.09-4.30, p = 0.027, respectively]. Clinical characteristics or subjective perception of symptom severity had no influence on participants' treatment choices. CONCLUSION Identifying PwRRMS with Risk-seeking behavior would be crucial to implementing specific educational strategies to manage information on disease prognosis, treatment expectations, and safety Risk knowledge.
-
High-Efficacy Disease-Modifying Therapies in People with Relapsing–Remitting Multiple Sclerosis: The Role of Risk Attitude in Treatment Decisions
The Patient - Patient-Centered Outcomes Research, 2020Co-Authors: Jorge Maurino, Javier Sotoca, Ángel P. Sempere, Luis Brieva, Carlos López De Silanes, Ana B. Caminero, María Terzaghi, Julia Gracia-gil, Gustavo SaposnikAbstract:Background Risk Attitude is defined as the willingness to tolerate Risk to achieve a greater expected return. Limited information is available on how relapsing–remitting multiple sclerosis people’s perceptions about disease trajectory and Risk Attitude may influence treatment choices. Methods A non-interventional study applying principles of behavioral economics was conducted to assess willingness to receive unwarranted high-efficacy disease-modifying therapy (DMT) according to best-practice guidelines. People with relapsing–remitting multiple sclerosis (PwRRMS) according to 2010 McDonald criteria completed a survey on symptom severity, Risk preferences, and management of simulated case scenarios mimicking the current treatment landscape. PwRRMS’s choice for high-efficacy agents was established as the participant’s selection of monoclonal antibodies for case scenarios with at least 2 years of clinical and radiological stability. Results A total of 211 PwRRMS were studied (mean age 39.1 ± 9.5 years, 70.1% female, mean Expanded Disability Status Scale score 1.8 ± 1.1). Almost 50% ( n = 96) opted for a high-efficacy DMT despite the lack of evidence of disease activity. Younger age and Risk-seeking behavior were associated with an increased likelihood of selecting unwarranted high-efficacy DMT [odds ratio (OR) 2.00, 95% confidence interval (CI) 1.02–3.93, p = 0.043, and OR 2.17, 95% CI 1.09–4.30, p = 0.027, respectively]. Clinical characteristics or subjective perception of symptom severity had no influence on participants’ treatment choices. Conclusion Identifying PwRRMS with Risk-seeking behavior would be crucial to implementing specific educational strategies to manage information on disease prognosis, treatment expectations, and safety Risk knowledge.
